Clinical trial
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born…
NCT00249821 · Merck KGaA, Darmstadt, Germany, Industry · Completed
Key facts
| NCT number | NCT00249821 |
|---|---|
| Title | Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age |
| Official title | Optimization of the Dosage Regimen With Growth Hormone Therapy in Children Born Small for Gestational Age. An Open Label, Randomized, Pilot Study, Comparing in Children Treated for 3 Years, the Efficacy of a Saizen® Treatment at the Same Dose Versus a Lower Maintenance Dose Prolonged During 1… |
| Acronym | SGA OPTIMIS |
| Lead sponsor | Merck KGaA, Darmstadt, Germany, Industry |
| Collaborators | Merck Serono S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Small Gestational Age (SGA) |
| Intervention type | Drug |
| Interventions | Saizen® |
| Enrollment | 22 |
| Start date | Feb 28, 2005 |
| Primary completion | Sep 30, 2007 |
| Completion | Sep 30, 2007 |
| First posted | Nov 7, 2005 |
| Last update posted | Sep 26, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: